What Is BPC-157? A Complete Research-Use-Only Guide

Research-use-only disclaimer. The information below summarizes peer-reviewed laboratory and animal-model literature on BPC-157 and is provided strictly for in vitro research and educational reference. BPC-157 is not approved by the FDA or any equivalent regulatory body for human or veterinary therapeutic use, is not a drug, supplement, food, or cosmetic, and must not be administered to humans or animals. All mechanistic effects described here are reported in animal studies or cell-based systems and have not been established in humans.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, abbreviated GEPPPGKPADDAGLV; molecular weight 1419.5 Da), originally identified as a partial sequence of a larger cytoprotective protein found in human gastric juice (Sikiric et al., 2018). It is studied in animal models for its reported effects on the nitric-oxide (NO) system, angiogenic signaling, and connective-tissue repair, and is supplied to qualified laboratories as a lyophilized reference peptide for benchtop research only.

1. Composition and Identity

BPC-157 is a linear pentadecapeptide — a chain of fifteen amino-acid residues joined by peptide bonds. The full primary sequence, as published in the Sikiric laboratory's foundational work and reproduced across subsequent literature, is:

• Sequence (one-letter): GEPPPGKPADDAGLV
• Sequence (three-letter): Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
• Length: 15 amino acids (pentadecapeptide)
• Molecular weight: 1419.5 Da (monoisotopic)
• Molecular formula: C₆₂H₉₈N₁₆O₂₂
• Designation: "BPC" = Body Protection Compound; "157" reflects the residue numbering of the fragment within the parent gastric-juice protein characterized by the Zagreb group.

Unlike many bioactive peptides, BPC-157 contains no cysteine residues and forms no disulfide bridges. Its high proline content (five of fifteen residues) is widely cited as the structural basis for its unusual proteolytic stability.

2. Origin: Where the Research Comes From

BPC-157 was first isolated and characterized as a fragment of a larger ~40-kDa cytoprotective protein identified in human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb, Croatia. The fragment was named for its proposed "body protection compound" activity in early rat gastric-lesion models (Sikiric et al., 2018; Sikiric et al., 1999). The vast majority of the published literature on BPC-157 originates from the Zagreb consortium, with parallel work from collaborating groups in Croatia, China, and the United States.

Important scope note: virtually all mechanistic data on BPC-157 are derived from in vitro assays or rodent (rat, mouse) injury models. Controlled human safety, pharmacokinetic, and efficacy studies have not been published in peer-reviewed clinical literature.

3. Stability Characteristics Reported in the Literature

BPC-157 is described in the source literature as unusually stable for a peptide of its length. Sikiric and colleagues have repeatedly characterized it as "stable in human gastric juice," a property attributed to its high proline content and the absence of cleavage-prone residue pairs (Sikiric et al., 2018). This stability profile is one reason the peptide is frequently selected as a benchtop reference compound for cytoprotection assays.

Standard handling variables that any laboratory should document on a per-lot basis:

• Storage temperature (lyophilized powder vs. reconstituted solution)
• Reconstitution buffer and pH
• Light exposure
• Freeze-thaw cycle count
• Time on the bench post-reconstitution

Material is supplied as a lyophilized powder for laboratory reconstitution only; no formulation, dosing, or administration claims are made or implied.

4. Signaling Pathways Most Frequently Cited

Across the peer-reviewed BPC-157 literature, two signaling axes are referenced most often:

4a. Nitric-oxide (L-arginine–NO) system

BPC-157 has been characterized in animal models as a modulator of the NO pathway, with reported interactions with both L-NAME (NO-synthase inhibition) and L-arginine (NO-synthase substrate) co-administration paradigms (Seiwerth et al., 2014). These interactions are observational within experimental systems and do not constitute claims about human physiology.

4b. Angiogenic and growth-factor signaling

In rat models of muscle and tendon injury, BPC-157 administration has been associated with up-regulated VEGF expression and accelerated formation of granulation tissue and new microvasculature relative to controls (Brcic et al., 2009; Seiwerth et al., 2018). The original Sikiric 1999 study likewise reported "evident angiogenic property" and stimulation of granulation-tissue formation in rats (Sikiric et al., 1999).

Again — these are reported mechanistic observations within experimental systems. They are not statements about human outcomes.

5. How BPC-157 Compares to Other Research Peptide Sequences

Peptide	Length / Origin	Pathways most cited
BPC-157	15 aa, fragment of human gastric-juice protein	NO system, VEGF/angiogenesis
TB-500	17 aa, synthetic fragment of thymosin β-4	Actin binding, cell migration
GHK-Cu	3 aa tripeptide + Cu(II)	Copper transport, gene-expression modulation

Sequence fidelity matters: a single residue substitution produces a chemically distinct peptide with potentially unrelated activity. Any BPC-157 reference material should be verified by mass spectrometry against the canonical 1419.5-Da sequence.

6. Verifying BPC-157 as Research Material

Before using any peptide for research, a qualified buyer should confirm the following per lot:

• Lot number matching every certificate to the physical vial
• Identity confirmation by mass spectrometry (expected mass ~1419.5 Da)
• Chromatographic purity by HPLC (typically ≥98% area)
• Net peptide content (corrected for water and counter-ion mass)
• A lot-specific Certificate of Analysis (COA) — not a generic specification sheet

Vague claims such as "99% pure" without lot-specific MS and HPLC traces are not sufficient for credible research use.

7. Common Misconceptions

Misconception 1: "Research-grade" implies human safety. It does not. Research-grade describes analytical identity and purity for laboratory use — nothing more. No regulatory body has cleared BPC-157 for human administration.

Misconception 2: A mechanism reported in animals will translate to humans. Effects observed in rat tendon-healing models or rodent gastric-ulcer assays cannot be assumed to occur, at the same magnitude, or with the same safety profile, in humans. The animal-to-human translation step has not been completed in published clinical trials.

Frequently Asked Questions

What does BPC-157 stand for?

BPC-157 stands for Body Protection Compound-157. The name was assigned by the original Zagreb research group to a 15-residue fragment of a larger cytoprotective protein found in human gastric juice (Sikiric et al., 2018).

What is the amino-acid sequence of BPC-157?

The published sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (one-letter: GEPPPGKPADDAGLV). It is 15 residues long with a molecular weight of 1419.5 Da and a molecular formula of C₆₂H₉₈N₁₆O₂₂.

Is BPC-157 approved for human or veterinary use?

No. BPC-157 is not approved by the FDA, EMA, or any other regulatory authority for human or veterinary therapeutic use. It is supplied strictly as a reference compound for in vitro research.

What signaling pathways are most often cited for BPC-157?

In animal studies, the most-cited pathways are the nitric-oxide (NO) system and VEGF-mediated angiogenic signaling (Seiwerth et al., 2014; Brcic et al., 2009). These are mechanistic observations within experimental systems, not claims about human physiology.

Is BPC-157 stable in solution?

The published literature describes BPC-157 as unusually stable for a peptide of its length, with the high proline content (five of fifteen residues) and absence of cysteine bridges cited as contributing factors. Stability in any given laboratory still depends on temperature, pH, light exposure, and freeze-thaw history — all of which should be documented per lot.

How does BPC-157 differ from TB-500 or GHK-Cu?

The three peptides have unrelated sequences, lengths, and most-cited pathways. BPC-157 (15 aa, gastric-juice origin) is most associated with NO and VEGF signaling; TB-500 (17 aa, thymosin β-4 fragment) with actin binding and cell migration; GHK-Cu (3 aa plus copper) with copper transport and gene-expression modulation. They are not interchangeable in research design.

How is BPC-157 verified as authentic research material?

Through a lot-specific Certificate of Analysis showing: mass-spectrometry identity (expected ~1419.5 Da), HPLC purity (typically ≥98%), net peptide content, and a matched lot number. Generic "99% pure" claims without per-lot MS and HPLC traces should be treated as unverified.

What is the half-life of BPC-157?

Published pharmacokinetic data on BPC-157 in humans do not exist in the peer-reviewed clinical literature. In animal models the parent compound is described as relatively short-lived in plasma but with effects persisting longer than the systemic exposure window — a profile the Zagreb group attributes to its stability in the gastrointestinal lumen and to downstream signaling cascades (Sikiric et al., 2018). Any specific half-life value for humans would not be supported by published data.

Why is BPC-157 reported as stable in gastric juice?

The Sikiric group has consistently characterized BPC-157 as resistant to degradation in human gastric juice, a property attributed to its compact 15-residue length, its five proline residues (which disrupt protease recognition motifs), and the absence of cysteine-bridge–dependent tertiary structure (Sikiric et al., 2018). This stability profile is one reason the fragment was selected for further mechanistic study after its identification in the parent gastric protein.

How is synthetic BPC-157 different from the native gastric protein?

The native parent is a much larger (~40-kDa) protein present in human gastric juice. BPC-157 is a synthetic 15-amino-acid fragment corresponding to residues within that protein, manufactured by solid-phase peptide synthesis. Synthetic BPC-157 is chemically defined to a single sequence (GEPPPGKPADDAGLV, 1419.5 Da), whereas the native protein is studied as part of a heterogeneous gastric proteome (Sikiric et al., 2018; Sikiric et al., 1999).

References

1. Sikiric P, Seiwerth S, Rucman R, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des. 2018;24(18):1990–2001. PMID: 29879879
2. Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972–1989. PMID: 29998800
3. Seiwerth S, Brcic L, Batelja Vuletic L, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121–1125. PMID: 23782145
4. Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60 Suppl 7:191–196. PMID: 20388964
5. Sikiric P, Seiwerth S, Mise S, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol Paris. 1999;93(6):479–485. PMID: 10672992

Last reviewed: 2026-05-25 by American Peptides Research Team.